免疫グロブリンA腎症における補体阻害:ミニレビュー
Jia Wei Teh1, Sinead Stoneman2, Michelle M O'Shaughnessy1
1School of Medicine, University of Galway, Galway, Ireland; Department of Nephrology, University Hospital Galway, Ireland.
Abstract:
Immunoglobulin A nephropathy (IgAN) is the most common immune-mediated glomerular disease worldwide. Advanced understanding of the role of complement in IgAN pathogenesis has motivated the development of complement inhibition as a therapeutic strategy. Iptacopan, a complement factor B inhibitor, is the first approved complement inhibitor for IgAN. Several other complement inhibitors are being studied in Phase II/III clinical trials. How best to integrate complement inhibition into the evolving treatment paradigm for IgAN remains a challenge. This review provides an overview of the role of complement in the pathogenesis and progression of IgAN and summarizes current and emerging complement-targeted IgAN therapies.
関連する概念動画
Nephrotic Syndrome I : Introduction
Complement System
Humoral Immune Responses
Acute Kidney Injury II: Pathophysiology
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...


